Interleukin 15 (IL15) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Interleukin 15 (IL15) - Pipeline Review, H1 2016

Interleukin 15 (IL15) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Interleukin 15 (IL15) - Pipeline Review, H1 2016
Published Jun 30, 2016
44 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Interleukin 15 (IL15) - Pipeline Review, H1 2016, provides in depth analysis on Interleukin 15 (IL15) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 15 (IL15), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 15 (IL15) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin 15 (IL15)
- The report reviews Interleukin 15 (IL15) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 15 (IL15) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 15 (IL15) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 15 (IL15) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 15 (IL15)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therape

  
Source:
Document ID
GMDHC0125TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Interleukin 15 (IL15) Overview61
Therapeutics Development73
  Interleukin 15 (IL15) Products under Development by Stage of Development71
  Interleukin 15 (IL15) Products under Development by Therapy Area81
  Interleukin 15 (IL15) Products under Development by Indication91
Interleukin 15 (IL15) Pipeline Products Glance102
  Late Stage Products101
  Early Stage Products111
Interleukin 15 (IL15) Products under Development by Companies122
Interleukin 15 (IL15) Products under Development by Universities/Institutes142
Interleukin 15 (IL15) Therapeutics Assessment167
  Assessment by Monotherapy/Combination Products161
  Assessment by Mechanism of Action172
  Assessment by Route of Administration192
  Assessment by Molecule Type212
Interleukin 15 (IL15) Companies Involved in Therapeutics Development233
  Amgen Inc.231
  Calypso Biotech SA241
  Digna Biotech, S.L.251
Interleukin 15 (IL15) Drug Profiles269
  AM-0015 Drug Profile261
  AMG-714 Drug Profile272
  BNZ-1321 Drug Profile291
  BNZ-1322 Drug Profile301
  CALY-002 Drug Profile311
  DB-039 Drug Profile321
  Monoclonal Antibody to Inhibit IL-2 and IL-15 for Oncology, Central Nervous System and Gastrointestinal Disorders Drug Profile331
  Recombinant Protein to Activate IL-15 for Prostate Cancer and Metastatic Cancer Drug Profile341
Interleukin 15 (IL15) Dormant Projects351
Interleukin 15 (IL15) Discontinued Products361
Interleukin 15 (IL15) Featured News &Press Releases376
  May 05, 2016: Celimmune Commences First-Ever Dosing with AMG 714 in Celiac Disease371
  Mar 31, 2016: Celimmune Commences Screening in Phase 2 Clinical Study in Refractory Celiac Disease Type II371
  Sep 23, 2015: Celimmune to Present Overview of Non-Dietary Celiac Disease Therapies in Development at Annual Celiac Support Association Meeting381
  Jun 22, 2015: Celimmune to Present Experimental Anti3IL315 Antibody AMG!714 at 16th International Celiac Disease Symposium391
  Jun 18, 2015: Admune Announces the First-in-Human Study of Heterodimeric IL-15 with Broad Applications for Cancer Immunotherapy391
  Dec 15, 2006: Genmab Announces AMG 714 Development Update401
  Mar 23, 2004: Amgen Announces Positive Humax-IL15 Interim Phase II Data401
  Jan 23, 2003: Genmab A/S Announces FDA Approval To Initiate Phase II Clinical Study Using HuMax-IL15401
  Sep 04, 2002: Genmab Announces Positive Results From Phase I/II Clinical Trial Of HuMax-IL15 For The Treatment Of Rheumatoid Arthritis401
  Jul 01, 2002: Genmab Announces The Human Antibody Therapeutic Drug HuMax-IL15 Effectively Treats Psoriasis411
  Oct 03, 2001: Genmab Initiates Phase I/II Clinical Trial With HuMax-IL15 For The Treatment Of Patients With Rheumatoid Arthritis421
Appendix432
  Methodology431
  Coverage431
  Secondary Research431
  Primary Research431
  Expert Panel Validation431
  Contact Us431
  Disclaimer441

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Interleukin 15 (IL15) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Interleukin-15-IL15-Pipeline-Review-H1-2016-2088-16075>
  
APA:
Global Markets Direct - Market Research. (2016). Interleukin 15 (IL15) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Interleukin-15-IL15-Pipeline-Review-H1-2016-2088-16075>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.